Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 89 Neoplasms 6 HER2-positive Breast Cancer 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Stomach Neoplasms 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Rectal Neoplasms 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Locally Advanced Breast Cancer 2 Inflammatory Breast Neoplasms 2 Colonic Neoplasms 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Solid Cancers 1 Salivary Gland Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1

Interventions

Control Groups 2 Atorvastatin 2 sacubitril and valsartan sodium hydrate drug combination 1 pertuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Trastuzumab 1 Sodium Chloride 1 Simendan 1 Pyruvic Acid 1 Population Groups 1 Ogivri 1 Metoprolol 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Eplerenone 1 Carvedilol 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Heart Failure × pertuzumab × Clear all

NCT04680442 2025-04-06

SCHOLAR-2

Population Health Research Institute

Phase 2 Recruiting

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡